CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-908-5179500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees14
OptionableOptionable
CorMedix (NYSEAMERICAN:CRMD) Frequently Asked Questions
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CRMD."
How were CorMedix's earnings last quarter?
CorMedix Inc. (NYSEAMERICAN:CRMD) announced its earnings results on Wednesday, November, 14th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.05. The biotechnology company had revenue of $0.37 million for the quarter, compared to analyst estimates of $0.05 million. View CorMedix's Earnings History.
When is CorMedix's next earnings date?
What price target have analysts set for CRMD?
2 Wall Street analysts have issued 1-year target prices for CorMedix's stock. Their forecasts range from $3.50 to $6.00. On average, they expect CorMedix's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price. View Analyst Price Targets for CorMedix.
What is the consensus analysts' recommendation for CorMedix?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CorMedix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for CorMedix.
What are Wall Street analysts saying about CorMedix stock?
Here are some recent quotes from research analysts about CorMedix stock:
- 1. HC Wainwright analysts commented, "We derive a value of $470M for Neutrolin using a 12% discount rate and 90% probability of success, along with a 23% effective tax rate, or a price per share of $3.50, taking into account $150M from additional value drivers (ex-U.S. sales, taurolidine gel formulation, and future medical device applications)—up from the prior $120M—and ~141M fully-diluted shares outstanding—including issuance of about 35M more shares due to warrant exercises and further stock issuances—as of end-2019. Our valuation of Neutrolin has risen to $350M from the previous $300M, based on higher peak sales potential." (1/18/2019)
- 2. According to Zacks Investment Research, "CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix's goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications. The Company's therapeutic candidates for cardiorenal disease may be small molecules, biologicals, devices and/or diagnostics (tests) that enable therapy. Its product pipeline includes: CRMD001, a unique formulation Deferiprone which is in development to prevent Contrast-Induced Acute Kidney Injury and to slow progression of Chronic Kidney Disease; CRMD002, a diagnostic test for urinary labile iron; CRMD003 (Neutrolin®, an antimicrobial/anticoagulant solution) is in development to prevent Catheter Related Bloodstream Infection; CRMD004, a pressure sensitive gel which has many uses, including extending the benefits of Neutrolin®. CorMedix Inc. is based in Summit, New Jersey. " (12/14/2018)
Has CorMedix been receiving favorable news coverage?
Media coverage about CRMD stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. CorMedix earned a coverage optimism score of 0.9 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent press coverage is very unlikely to have an impact on the stock's share price in the near future.
Are investors shorting CorMedix?
CorMedix saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 13,846,044 shares, a drop of 3.4% from the December 14th total of 14,328,775 shares. Based on an average daily volume of 1,727,019 shares, the short-interest ratio is presently 8.0 days. Approximately 13.8% of the shares of the stock are sold short. View CorMedix's Current Options Chain.
Who are some of CorMedix's key competitors?
Some companies that are related to CorMedix include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Ampliphi Biosciences (APHB).
Who are CorMedix's key executives?
CorMedix's management team includes the folowing people:
- Mr. Khoso Baluch, CEO & Director (Age 61)
- Mr. Robert W. Cook, Chief Financial Officer (Age 63)
- Mr. John L. Armstrong Jr., Head of HR & Exec. VP of Technical Operations (Age 75)
- Ms. Elizabeth Masson, Exec. VP & Head of Clinical Operations (Age 40)
- Mr. John Ortiz, VP of Regulatory Affairs & Quality Assurance
Who are CorMedix's major shareholders?
CorMedix's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Steward Partners Investment Advisory LLC (0.07%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Institutional Ownership Trends for CorMedix.
Which major investors are buying CorMedix stock?
CRMD stock was purchased by a variety of institutional investors in the last quarter, including Steward Partners Investment Advisory LLC. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Jr John L Armstrong, Khoso Baluch, Mehmood Khan, Myron Kaplan, Robert W Cook and Steven W Lefkowitz. View Insider Buying and Selling for CorMedix.
How do I buy shares of CorMedix?
Shares of CRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CorMedix's stock price today?
One share of CRMD stock can currently be purchased for approximately $1.71.
What is CorMedix's official website?
How can I contact CorMedix?
CorMedix's mailing address is 1430 US Highway 206 Ste 200, BEDMINSTER, NJ 07921-4602, United States. The biotechnology company can be reached via phone at +1-908-5179500.
MarketBeat Community Rating for CorMedix (NYSEAMERICAN CRMD)
MarketBeat's community ratings are surveys of what our community members think about CorMedix and other stocks. Vote "Outperform" if you believe CRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
